Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
2023
focused on complementary technologies Acquired_by_Pfizer |
| gptkbp:advertising |
focus on niche oncology markets
|
| gptkbp:advocacy |
supports cancer patient organizations
|
| gptkbp:businessModel |
focused on innovation and partnerships
|
| gptkbp:CEO |
gptkb:David_Epstein
|
| gptkbp:clinicalTrials |
presented at major conferences
utilizes advanced technologies includes multiple candidates conducted in various cancer types ongoing for multiple drugs |
| gptkbp:collaborations |
with healthcare providers
with other biotech firms with pharmaceutical companies with leading cancer centers with_Genentech |
| gptkbp:community_engagement |
supports cancer research initiatives
|
| gptkbp:community_outreach |
engages in local health initiatives
|
| gptkbp:community_service |
focus on overall survival
involves in policy discussions. programs for drug access |
| gptkbp:employees |
over 1,000
|
| gptkbp:financialPerformance |
strong growth trajectory
|
| gptkbp:focus |
cancer treatment
|
| gptkbp:focus_area |
targeted therapies
|
| gptkbp:founded |
1998
|
| gptkbp:founder |
Clay_B._Siegall
|
| gptkbp:global_presence |
operates in multiple countries
|
| gptkbp:headquarters |
gptkb:Bothell,_Washington
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seagen
|
| gptkbp:investmentFocus |
in R&D
provides updates quarterly |
| gptkbp:leadership |
diverse executive team
|
| gptkbp:market |
approximately $30 billion (2021)
|
| gptkbp:notableFeature |
Adcetris
Tukysa |
| gptkbp:partnerships |
with academic institutions
collaborates_with_Merck with_Astellas_Pharma |
| gptkbp:patentCitation |
strong patent portfolio
|
| gptkbp:patentType |
for_Adcetris_in_2011
for_Tukysa_in_2020 |
| gptkbp:platforms |
integrates biology and chemistry
|
| gptkbp:publications |
contributes to oncology literature
|
| gptkbp:regulatoryCompliance |
for new therapies
|
| gptkbp:research |
Dr._Roger_Dansey
|
| gptkbp:research_areas |
oncology
|
| gptkbp:research_focus |
antibody-drug conjugates
|
| gptkbp:revenue |
$1.1 billion (2020)
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:stockExchange |
SGEN
|
| gptkbp:supportRole |
composed of industry experts
|
| gptkbp:sustainability_initiatives |
environmental responsibility initiatives
|
| gptkbp:targetMarket |
into international markets
|
| gptkbp:training |
emphasizes continuous learning
|
| gptkbp:tributaryOf |
includes late-stage candidates
|
| gptkbp:type |
public company
|